The MFDS has initiated a pilot operation of the Pre-notification System for Changes in Pharmaceutical Marketing Authorization

 


Previously, there was a challenge in predicting the approval date for changes, as once the review by the MFDS was completed for a change approval application, the approval process would proceed without separate notification to the company.


In response, the MFDS has announced the pilot operation of the Pre-notification System for Changes in Pharmaceutical Marketing Authorization starting from December 18th. This initiative aims to increase predictability for changes in drug authorization schedules and ensure a stable supply of pharmaceuticals in the domestic market.


The Pre-notification System for Changes in Pharmaceutical Marketing Authorization is a system in which the MFDS and pharmaceutical manufacturers or importers, prior to processing changes in product authorization, engage in pre-discussion with the applying company to consider the company's manufacturing or import schedule. Subsequently, the applying company submits a pre-notified application, allowing them to obtain the modification approval on the desired date.


The pilot project will be in operation until the end of December 2024, and a formal decision on whether to proceed with regular operations will be made after evaluating and reviewing the results of the pilot phase.



👉 Contact GCA

Tel. +82-31-360-8180
Email: forest.lee@gca-kr.com


Comments

Popular posts from this blog

South Korea Mandates Fire Extinguishers in All Vehicles with Five or More Seats

Upcoming Changes to Child Car Seat Safety Standards in Korea

KCs Ex Certification | Compatibility with IECEx and ATEX